Director/PDMR Shareholding
Faron Pharmaceuticals Ltd. announced that Sirpa Jalkanen, a scientific founder and closely associated person to a board member, subscribed to 100,008 ordinary shares at €0.5 per share on March 24, 2026, as part of the company's rights issue. This transaction, totaling €50,004, was conducted on the Nasdaq First North Growth Market and is detailed in a notification of dealing form.
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Company announcement | March 25, 2026 at 10:00:00 EET |
TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Sirpa Jalkanen, Scientific founder of the Company and spouse of Board member Markku Jalkanen, subscribed 100,008 ordinary shares in Faron at price of €0.5 per share on 24 March 2026, pursuant to the Rights Issue announced by the Company on 10 March 2026.
Further details are set out in the Notification of Dealing Form below.
| a. | Name | Sirpa Jalkanen |
| 2 | Reason for notification | |
| a. | Position/Status | PCA |
| b. | Initial notification/ Amendment | Initial Notification |
| a. | Name | Faron Pharmaceuticals Ltd. |
| b. | LEI | 7437009H31TO1DC0EB42 |
| a. | Description of the financial instrument, type of instrument Identification Code | Subscription for new ordinary shares, pursuant to a rights issue ISIN: FI4000153309 |
| b. | Nature of the transaction | Subscription |
| Price(s) per share (p) | Volume(s) | |
| EUR 0.5 | 100,008 | |
| d. | Aggregated information Volume Price | Transaction details (a) (1): Volume 100,008 Unit price: 0.5 EUR |
| f. | Place of the transaction | Nasdaq First North Growth Market |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.